risk factors. However, when adjusted for additional laboratory abnormalities, differences did not persist for progression, but did for survival advantage of Asians. The median rate of decline in eGFR (in millilitres per minute per 1.73 m
Introduction
The prevalence and incidence of chronic kidney disease (CKD) has been the focus of numerous publications over the last 5 years. Importantly, those who reach end-stage renal disease (ESRD) are a small proportion of those with identified CKD, but, nonetheless, both groups consume large amounts of resources. The ability to predict progression remains a goal of clinicians and researchers. Recently, increasing attention has been drawn to ethnic differences in both rates of progression and outcomes on dialysis. Much of the literature is US based and compares African-American outcomes to Caucasians. Recently, genes predicting kidney disease in Blacks have been described [1, 2] , adding credence to the hypothesis that there may be genetic differences which account for differential proportions of patients on dialysis. Ethnicity has been observed to be a predictor of mortality and rate of progression of CKD. Compared to Caucasians, Hispanic CKD patients have a higher incidence of ESRD but a better mortality rate [3] . In the United States, Blacks have a similar CKD prevalence as Caucasians but have a 5-fold higher rate of ESRD incidence, suggesting a faster rate of progression through CKD [4] . American Asians have an ESRD incidence between that of Blacks and Caucasians yet have an improved survival once on dialysis [5] . Compared to Caucasians with similar GFR, Asians, when followed up over time, have a higher incidence of ESRD [6] ; however, data supporting differential rates of decline in renal function have not been available. This is due to the fact that the majority of data on ethnic differences in rates of CKD progression has relied heavily on United States Renal Data System (USRDS) data which describe both incidence and prevalence of ESRD, but do not provide sufficient information about the history of patients prior to renal replacement therapy (RRT) commencement. Thus, the hypothesis that specific groups have faster rates of progression through CKD has not been directly examined. In addition, there is limited data on ethnic groups such as Oriental and South Asians (OA and SA, respectively) who comprise large non-Black groups in the US and other developed countries. Furthermore, multiple sources of bias may be contributing to results derived from observational data from health systems in which individuals have unequal access to health care.
The current analysis describes differences in the documented rates of progression of renal dysfunction and survival amongst a cohort of CKD patients in a universal health care system followed up by nephrologists from the time of diagnosis of CKD, with ethnicity as the exposure of interest. The universal health care system in Canada provides equal access to all Canadian citizens and landed immigrants, irrespective of age or socioeconomic status. We have previously shown that laboratory parameters known to predict outcome differ across ethnicities such that, compared to Caucasians, OA and SA have a higher prevalence of worse laboratory parameters at any given stage of CKD [7] .
Materials and methods

Study design
This is an observational cohort study which examines the time to RRT (dialysis and transplantation) and death and the rates of renal progression in several ethnic groups followed up from the time of registration in a provincial database of all patients referred to nephrologists.
Description of environment and derivation of the cohorts
In British Columbia, all patients with CKD are registered in a database at the time of referral to a nephrologist if they fulfil certain criteria. These include referral to a nephrologist and the presence of CKD (defined as estimated GFR (eGFR) < 60 mL/min/1.73 m 2 alone or, if eGFR > 60 mL/min/1.73 m 2 , there is evidence of kidney damage from urinalysis or based on biopsy or ultrasound results; histological diagnoses are not mandatory for the database). eGFR was calculated using the abbreviated MDRD formula [8] , based on standardized creatinine as described below. Note that both the standard MDRD formula and the recently published ethnic-appropriate formulae were applied to the Asian group within the cohort [9, 10] . Self-reported race (SRR) is recorded and chosen by the patients from a list that includes OA, Caucasian, SA, First Nation, Filipino or other, usually as determined by traditional countries of origin. At the initiation of the database (year 2000), this field was not mandatory, and thus, some patients may or may not have completed the field. For the purposes of the analysis, we focussed on those patients who were identifiable (using the SRR field) as Caucasian, SA or OA (given that these were the most prevalent ethnicities in BC) and in whom a complete data set upon registration was available. This is defined as demographics, comorbidities and laboratory parameters including serum, creatinine, phosphate, calcium, intact parathyroid hormone (iPTH), albumin and haemoglobin levels. Proteinuria was defined using categories of negative, moderately increased or severely increased based on either urine albumin: creatinine ratio (UACR) (0-5, 5-30, >30 mg/mmol creatinine, respectively) or urine dipstick (0-1, 1-3, >3 g/L, respectively), whichever was available or worse. In addition, we included variables of interest such as blood pressure at time of registration, use of angiotensin converting enzyme (ACE) inhibitors (ACEI) or angiotensin receptor blockers (ARB) and use of vitamin D analogues or erythropoietin-stimulating agents (ESA). All laboratory results are automatically uploaded to the database and are thus available for each patient once registration occurs (including historical values). Medications for CKD non-dialysis patients are paid for provincially (such as ESA, iron therapies, vitamin D analogues and calcium supplements) and are thus tracked after the patients are registered; no medications at the time of registration would be paid for and are, therefore, not captured in the database. Other baseline data collected include age, gender, presence of diabetes and eGFR (derived from standardized creatinine values and using the MDRD formula, see below for details). After registration in the database, all such data in addition to RRT status, transplant status and comorbidities are recorded until the patient dies or is lost to follow-up. All required information had already been collected and was contained in the database. No further additional investigations were performed on the patients for the purposes of this analysis. Ethics approval for these analyses was obtained from the appropriate institutional ethics boards.
Details regarding creatinine measurements and estimation of GFR Creatinine measurements at all laboratories in British Columbia have been standardized with an isotope dilution mass spectrometry (IDMS) reference for application in a province-wide eGFR reporting initiative based on an IDMS traceable format of the MDRD formula [11] . Therefore, although creatinine measurements were performed in different laboratories, they have been standardized, are directly comparable and are, therefore, used in the MDRD formula. The equations in the case of OA were calculated for the purposes of this analysis only and were not available to clinicians.
Outcomes of interest
There are two primary outcomes of interest, all-cause mortality and starting RRT (defined as requiring dialysis or receiving a renal transplant). Secondary outcomes of interest are the rate of decline in GFR (in millilitres per minute per 1.73 m 2 per year), the combined endpoint of allcause mortality and needing RRT and all-cause mortality after starting RRT.
The extent to which any differences across SRR in our primary and secondary outcomes are explained by known predictors of such outcomes was investigated using multivariate modelling techniques. This includes age, sex, diabetes, presence of hypertension [systolic blood pressure (SBP) > 130 mmHg, diastolic blood pressure (DBP) > 80 mmHg] or cardiovascular disease, medication use (ACEI, ARB, statins or vitamin D analogues), degree of proteinuria and laboratory abnormalities.
Statistical methods
Descriptive statistics for Caucasians, OA and SA are presented as the mean with standard deviation or median with interquartile range, depending on the underlying distribution. Continuous and categorical variables were compared amongst races using ANOVA F statistical distribution or Kruskal-Wallis and chi-square tests, respectively. We described the event rates (expressed as event numbers per 1000 patient-years) and 95% confidence intervals for the cohort as a whole and by SRR groups. The event rates for each outcome (total deaths, deaths before RRT, deaths after RRT, RRT, and composite of RRT/deaths) are calculated as the ratio of the number of events and the total patientyears of follow-up for each event.
We used the Cox proportional hazards model to examine the association of race and overall mortality after adjusting for all covariates associated with survival as well as race. In this analysis, we modelled the initiation of dialysis as a time-varying covariate.
However, because more than one event (RRT initiation or death) could occur, which alters the probability of experiencing the other event, we were interested in the cumulative incidence of a specific event (RRT or death). We used a competing risk approach to examine the extent to which the cumulative probabilities of the composite outcomes reflected RRT or death at each follow-up time by SRR. Separate cumulative incidence curves for the cumulative probability of RRT (without censoring death) and for the cumulative probability for death before RRT (without censoring RRT events) were obtained using the competing risk approach [12, 13] . We used the regression analysis approach proposed by Fine and Gray for the direct regression modelling of the effect of covariates on the cumulative incidence function for competing risks data to examine the association of SRR and RRT/death after adjusting for (i) demographics, eGFR level, comorbidities and use of ACEI/ARB/vitamin D/statins or (ii) all of the above and laboratory abnormalities.
The association of SRR and decline of kidney function was further explored utilizing the rate of eGFR progression. All eGFRs between baseline eGFR and study end date (ending due to RRT, death, lost to follow-up or study period end) were extracted for analysis. We first calculated the annual rate of progression of eGFR for each patient by regressing the eGFR values on the time when eGFR was taken. We then explored the association of eGFR progression rate and SRR by weighted linear regression model, with the reciprocal of the standard error of the progression rate of each patient as the weights. Log-rank test P-value: 0.0147 All analyses were performed with both the usual MDRD and the Asian-adjusted formulae for eGFR [9, 10] , but for the purposes of clarity, we present only those results using the usual MDRD formula. Note that all results were in the same direction and offer the same conclusions albeit with some important differences which are explained in the text, when they occur.
All tests were two-sided with P-values < 0.05 being considered significant. All statistical analyses were performed in SAS software, version 9.1 (SAS Institute, Cary, NC).
Results
Derivation of the cohort and patient characteristics Figure 1 describes the derivation of the cohort, while Table 1 describes the clinical and laboratory characteristics of the total cohort and by SRR categories of Caucasian, OA and SA. Note that there are significant differences between the different SRR groups with respect to all variables, though of particular note are eGFR at the time of referral, age (SA are younger) and the use of ACEI, ARB, vitamin D and statins (less usage by SA). Table 2 describes the event rates for death occurring before and subsequent to RRT for the overall cohort and by SRR groups. Of note, the cohort of 3444 persons incurred 825 deaths, of which 474 were prior to RRT and the remainder were after initiation of RRT. Older patients were more likely to die than younger ones, as were males more likely to die than females (results not shown). The rate of death for Caucasians prior to the initiation of RRT was significantly higher (44 per 1000 patient-years vs 23 and 31 for SA and OA, respectively, P < 0.01). However, the rates of death after commencing dialysis were comparable. Figure 2 describes the Kaplan-Meier patient survival curves by SRR (and includes all deaths before and after RRT); there is a significant difference in that Caucasians are more likely to die than OA or SA (P = 0.0147).
Event rates
Survival hazard ratios with dialysis status as a time-varying covariate Table 3 describes the univariate and multivariate results of Cox proportional hazards modelling of the overall patient survival data. Each covariate was examined one at a time to explore factors associated with patient survival (see the univariate columns). All baseline parameters, except SBP, were statistically associated with patient survival.
Since SRR is our primary factor of interest, a model was fitted adjusting for all available covariates that are associ- Differences in mortality and CKD progression by raceated with survival (see the multivariate columns in Table 3 ). The model controlled for the initiation of dialysis, using it as a time-varying covariate. The interaction term between SRR and eGFR level on patient survival was not statistically significant (P-value = 0.2083). Our findings confirm that there are survival differences among ethnic groups of CKD patients not explained by known predictors of mortality, with OA and SA having better survival than Caucasians with adjustments for demographics, eGFR level, comorbidities, use of ACEI/ARB/vitamin D/statins and laboratory abnormalities. Figure 3 presents the Kaplan-Meier cumulative incidence curves by ethnicity for the composite outcome of RRT or death, probability of RRT and probability of death before RRT. This shows that the probability of commencing RRT is far above the risk of death prior to RRT in all ethnic groups. Figure 4 compares the difference among ethnicity separately for each outcome of interest: RRT, death prior to RRT and the composite outcome of RRT or death. This figure indicates that the Caucasian group has the lowest probability of initiating RRT and highest risk of death before RRT compared to the OA and SA groups, while the composite outcomes of death and commencing RRT are comparable among the three ethnicities. Note that separate cumulative incidence curves for the probability of RRT without censoring death and for the probability for death before RRT without censoring RRT were obtained using the competing risk approach. Table 4 ['univariate hazard ratios' (HR)] demonstrates univariate differences between HR comparing SRR groups for the outcomes of interest: both OA and SA groups have a higher risk of progressing to RRT and a lower risk of death prior to RRT compared to Caucasians.
Time to event (RRT and death): a competing risk analysis approach
Adjusted hazard ratios using a competing risk approach
We explored ethnic differences in the probability of RRT and death prior to RRT using a competing risk approach with age, sex, diabetes, cardiovascular disease (CVD), blood pressure, baseline eGFR levels and use of ACEI/ ARB/vitamin D/statins included in the model ('partially adjusted model'). After adjusting for these characteristics, the OA group continued to maintain a higher risk of progressing to RRT and lower risk of death prior to RRT (Table 4 , only the HR for SRR was shown). Table 4 describes adjusted HR for ethnic groups using a competing risk approach with demographics, comorbidities and baseline laboratory parameters included in the model ('fully adjusted model'). When further adjusting for laboratory parameters, the risk of progressing to RRT is no longer significant among the ethnic groups. However, irrespective of the adjustments for demographics, comorbid conditions and laboratory abnormalities, Caucasians remain significantly more likely to die prior to RRT.
eGFR progression rate Table 5 summarizes the annual rate of change of eGFR by SRR group. Consistent with the results of competing risk analysis, Caucasians have the slowest level of eGFR decline at any baseline level of eGFR compared to OA and SA (P < 0.01). This finding remains significant in the weighted regression model after adjusting for patient demographic, comorbidity and laboratory characteristics (OA: β = −1.49, SE = 0.24, P < 0.001; SA: β = −0.68, SE = 0.22, P = 0.001).
Impact of different equations on results
All of these analyses were recalculated using adjusted MDRD published formulae for Asian patients (using both Japanese and Chinese adjustments [9, 10] ). Note that the results for each key outcome: eGFR at time of referral, univariate and multivariate hazards ratios for death with RRT as a time-varying covariate and for univariate and multivariate modelling of RRT using a competing risk approach, as well as the annualized slope of progression demonstrate results similar to those presented above (data not shown).
Discussion
To our knowledge, this is the first analysis to compare time to RRT (dialysis or transplantation), mortality and rates of progression amongst three different ethnic groups exposed to the same care within a universal health care system. We describe a more rapid rate of decline for Asians (both OA and SA) relative to Caucasians. Using a competing risk approach, differences in progression rates are not explained by high competing mortality risk in Caucasians prior to dialysis. After adjusting for renal comorbidities, as evidenced by laboratory abnormalities, the risk of starting RRT becomes comparable between OA, SA and Caucasians.
In addition, we demonstrate that Asians have better overall survival, despite the rapid progression and commencement of RRT. This holds true whether we examine survival before or after RRT. To our knowledge, this finding has not been previously reported. Both OA and SA have faster rates of renal progression, which appear to be explained by differences in the metabolic abnormalities of CKD existing at any given level of eGFR. This may suggest that an individual's 'burden of kidney disease' (reflecting how close they are to complete loss of the organ and need for RRT) is not only reflective of the absolute eGFR but also of the metabolic abnormalities present at any stage. Alternatively, these metabolic abnormalities may contribute to renal progression or the presence of such abnormalities may bias the nephrologist into starting RRT earlier. It is not possible to determine which, if any, of these alternative explanations is most plausible and, in fact, they are not mutually exclusive. Note that the fast rate of progression in this cohort distinctly contrasts with that of a Japanese cohort report [10] . As these are individuals of Asian descent living in a western environment and exposed to potentially different diet and environments, it may be that those factors contribute to progression in North America. Alternatively, as our number of Japanese patients as opposed to Chinese patients is relatively small, it may be that these two different groups have different rates of progression within the Asian cohort. Unfortunately, the ability to describe this in more detail was beyond the scope of this paper and analysis.
We have previously shown that, at every level of eGFR, Asian groups have significantly worse laboratory abnormalities compared to Caucasians [7] . This includes anaemia, hyperphosphataemia, hypocalcaemia, hypoalbuminaemia and hyperparathyroidism. These laboratory abnormalities have been associated with cardiovascular disease; therefore, this finding of better short-term and long-term outcomes is interesting. It may be that these abnormalities identify worse renal impairment and/or contribute to progression in Asian populations, but do not contribute to cardiovascular disease or mortality in these populations. There may be specific differences between ethnic groups which include genetics, social and environmental factors (such as diet, exercise, alcohol, smoking and other exposures). It is not possible to understand the impact of these more 'environmental' factors on the outcome due to the lack of detailed information about these in the current database.
As has recently been described in the African-American population [1, 2] , there may be true genetic differences in response to injury and to cardiovascular disease susceptibility. These will be explored in future studies. As a corollary to genetic variability, it may be that different groups of individuals have measurable biologic differences (such as the degree and nature of inflammatory response) or exposures and reactions to specific dietary or metabolic products. We have recently described biomarker differences in CKD patients randomized to low vs high haemoglobin targets and found that those with the greatest degree of left ventricular growth had the highest levels of inflammatory markers [14] . Interestingly, the subset of Asians included in that study had the lowest level of C reactive protein (CRP) of all participants.
Despite similar rates of diabetes, OA appear to have less reported cardiovascular disease relative to Caucasians. This too is an intriguing observation, but cannot be further explored due to the nature of the database. These data contribute to a growing body of knowledge that supports ethnic differences in the rates of CKD progression and survival [15] . However, further investigations are needed to identify the specific explanation for these differences.
The information presented here is worthwhile as it can direct RRT planning, given the greater propensity of certain ethnic groups to progress through later stages of CKD more quickly.
The particular strengths and insights gained from this paper include the focus on a non-Black non-Hispanic group of individuals, all of whom are exposed to a universal health care system. Given that there are no disincentives to care prior to dialysis in this system and no discrimination on the basis of age or socioeconomic status, the impact of these variables on outcomes is obviated. To date, the majority of research in this area has relied on USRDS ESRD incidence data and survival amongst ESRD patients and has not followed up CKD patients over time, prior to dialysis start. Alternatively, studies have focused on groups of insurance company patients with unequal access to health care before registration in the database and possibly during the observation period. In other data sets, like USRDS, the competing risk of death may be the explanation for different observed incidence rates of ESRD between different ethnic groups. The current analysis ensures complete follow-up of patients over time, prior to RRT, and thus we are able to calculate rates of decline in GFR as well as incidence rates of ESRD and have dealt with the competing risk of death during CKD. These aspects add strength to this analysis.
The limitations and weaknesses of this study include the fact that this is a referred cohort and thus may not apply to the general un-referred CKD population. This is an observational study with all the inherent biases and limitations thereof. However, due to careful selection of the cohort, characterization of the cohort at baseline with commonly measured parameters known to impact on renal progression and cardiovascular disease outcomes and complexity of the analyses we have performed, we have mitigated much of the usual risks of such an analysis. Although there were statistically significant differences in renal function at baseline, these may not be clinically significant and suggest that patients of all ethnic groups were similarly referred to nephrologists, arguing against a meaningful referral bias.
It remains possible that there is a confounding effect of ethnicity, in that it is a surrogate for diet, lifestyle, social network or other factors, but this can only be a hypothesis. Of course, other unknown confounders not captured in the database were not controlled for.
In order to mitigate the potential flaws with using the usual MDRD estimation, we did explore the consistency of the findings, using two alternative published OA equations. Note that, by using both conventional MDRD and either of the adjusted MDRD Asian equations, the same results were obtained. More importantly, however, we note that irrespective of which equation is used, since each person essentially served as their own control, irrespective of the 'true' eGFR, the rate of progression remained faster in Asians compared to Caucasians. The commencement of dialysis or receipt of a transplant is a key outcome and not subject to the potential bias of calculation errors. In our previous publication, using a modified equation with better accuracy in Chinese patients only accentuated the differences between Caucasians and Asians [7] , so irrespective of equations used, our findings remain consistent. Perhaps most pertinent to this discussion is that the clinicians caring for these patients did not have access to any adjusted equations, and in as much as the direction of care may be influenced by laboratory data, we elected to present the MDRD equations for simplicity and clarity. It is not clear how or if knowledge of different eGFR values may impact clinical decision making and care plans.
Conclusions
We have demonstrated in a large referred cohort of CKD patients in a universal health care system with unrestricted care prior to RRT that OA and SA have a shorter time to ESRD, faster rates of renal decline and better survival compared to Caucasians in the same system. Further investigation into the implications for resource planning, as well as to determine the significance of environmental or genetic factors, is warranted.
